T-cell immunotherapies

Celgene Corporation (NASDAQ: CELG) and Juno Therapeutics Inc (NASDAQ: JUNO) recently announced a 10-year collaborative partnership to develop T-cell immunotherapies, under which the former will be buying $1 billion stake in the latter at $93 per share. Hans Bishop, Juno Therapeutics CEO, was on...